TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: verbal abilities improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microporosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence requiring treatment rate
Endpoint domain: Mortality/survival
Primary endpoint: Return to regular activity time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in facial wrinkles and folds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean transfusion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Left ventricular time-velocity integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: E/E' ratio (LV filling pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: filling pressure at rest and at peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neck pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean nausea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: number of vomits
Endpoint domain: Adverse events/effects
Primary endpoint: EC50 of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post treatment PNIF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in rhinorrhea, nasal congestion, throat itching and cough symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hematologic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ESS (Epworth Sleepiness Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in FVAS (Functional Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in FIQ (Fibromyalgia Impact Questionnaire) general and morning tiredness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Daily insulin dose (units/kg BW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of ischemic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to the first ischemic event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rhinosinusitis Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Analogic Scale of symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rhinomanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDA-defined valvulopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best corrected visual acuity (BSCVA) of 20/32 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage change in central endothelial cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of type B tympanogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of type B tympanogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal arteriolar calibre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of manual ventilator setting changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in LDL subfraction distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery rate after 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Duration of the index episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants remaining depressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speed of image pair evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in identifying image pairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No vomiting overall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No significant nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instituted a smoking ban
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: insertion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: advancement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of adenoma recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: fewer inaccuracies of physician utterances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fewer inaccuracies of mother utterances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preference for remote-simultaneous service
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Change in blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute CD4+T-cell count recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean cost for purchase, implantation, diagnosis and treatment of complications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: lopinavir 24 h area under the plasma concentration-time curve (AUC(24 h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum plasma concentration (C(max)) for once-daily treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12 h plasma concentration (C(12 h)) for twice-daily treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: moderate physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common carotid IMT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade of ACO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEC outgrowth on hydrogel IOL surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macule counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: diffuse hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self-perceived voice quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-month mortality
Endpoint domain: Mortality/survival
Primary endpoint: CDAI ≤10 at 6 months postswitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in pain and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of fewer than 1.5 lines of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild radiation complications (radiation vasculopathy)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean pain value reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vesicular cholesterol percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cholesterol crystal observation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histamine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tryptase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mid-peripheral near visual acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in self‐monitored blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in 1,5‐anhydroglucitol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of AO (Alveolar Osteitis)
Endpoint domain: Adverse events/effects
Primary endpoint: anxiety/depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mindfulness skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: P(det.open)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P(det.close)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P(det).Q(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean rate of decline in cognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: median percentage decrease in the summary score for dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensation of burning at the site of application
Endpoint domain: Adverse events/effects
Primary endpoint: short-term mortality prediction
Endpoint domain: Mortality/survival
Primary endpoint: Number of flares
Endpoint domain: Adverse events/effects
Primary endpoint: Osteoclast differentiation and activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of incontinence episodes per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: morning pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in modified Rodnan skin thickness score (MRSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptoms (mean CAPS total scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary aldosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mRS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: BI score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: parent's perceived understanding and ability to cope with and control asthma
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: microhardness values of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: curative-markedly effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in physical signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: erections adequate for sexual intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of sexual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency of use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: plasma cocaine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 1-year change in the volumes of third ventricle, midbrain, and frontal lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of disseminated tumor cells in peripheral blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma hyaluronan concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Ringer's acetate retained in the intravascular space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to complete the task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of anagrams successfully solved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue-oxygenation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to the programme
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in outcomes measures immediately following rehabilitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of complex plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: serum ICAM-1 and hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Free from major adverse cardiac events
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulated cost level
Endpoint domain: Resource use
Primary endpoint: Rate of conversion to echocardiographic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total drinking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCLA activity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Chromium blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Response to clozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to haloperidol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive symptoms response to clozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBeAg positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HBV-DNA positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUDRC for wheal and flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Impact-RhinoQOL score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Lund-Kennedy score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and severity of crusts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary neutrophilia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: alveolar injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Engagement in telepsychotherapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Steroid-sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of cold sore lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall severity of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disruption of prior uterine incisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality relevance ratio
Endpoint domain: Resource use
Primary endpoint: Number of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behçet's Disease Quality of Life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dysuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: final efficacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean daily intake of fruits and vegetables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood pressure recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of positioning and deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: postoperative pouch volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: SMFA-D scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HPV positive tumour rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anxiety sensitivity decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion-to-background ratio (LBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of DQB1 alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative scores of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bleeding score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Empowerment in seeking treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-breast tumor recurrence (IBTR)
Endpoint domain: Mortality/survival
Primary endpoint: Postoperative colicky pain
Endpoint domain: Adverse events/effects
Primary endpoint: Need for medical treatment for symptoms or complications
Endpoint domain: Adverse events/effects
Primary endpoint: Acute readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in HBV‐DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CTP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MELD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in function (FFbH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minimum alveolar concentration-hour of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-tidal concentrations of sevoflurane at the end of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients requiring supplemental boluses of fentanyl
Endpoint domain: Adverse events/effects
Primary endpoint: Intradiaytic morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: overall mortality within 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Condom acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate Variability (HRV) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SLEDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Avonex treatment discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum cystometric bladder capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary volume at first unstable contraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: patients' assessment of efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in drinks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in drinks per occasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in binge drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of attempts to complete intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successful first attempts at intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required to complete intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: penetrability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean SL at MSL and EC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective perception of effort intensity (Borg scale)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of dizziness at EC
Endpoint domain: Adverse events/effects